Filtered By:
Countries: UK Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 74163 results found since Jan 2013.
Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom
Conclusions. A high proportion of the most common TDR in subtype B infections in the United Kingdom is derived by onward transmission from treatment-naive patients.
Source: Clinical Infectious Diseases - August 10, 2015 Category: Infectious Diseases Authors: Mbisa, J. L., Fearnhill, E., Dunn, D. T., Pillay, D., Asboe, D., Cane, P. A., for the UK HIV Drug Resistance Database, on behalf of the UK HIV Drug Resistance Database, Aitken, Asboe, Pozniak, Cane, Castro, Dunn, Fearnhill, Porter, Tostevin, Chadwick, Chu Tags: HIV/AIDS Source Type: research
Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters
Discussion. Despite the increase in non-B subtypes associated with heterosexual transmission, MSM and PWID are at risk for non-B infections. Crossover of subtype C from heterosexuals to MSM has led to the expansion of this subtype within the United Kingdom.
Source: The Journal of Infectious Diseases - March 29, 2016 Category: Infectious Diseases Authors: Ragonnet-Cronin, M., Lycett, S. J., Hodcroft, E. B., Hue, S., Fearnhill, E., Brown, A. E., Delpech, V., Dunn, D., Leigh Brown, A. J., on behalf of the United Kingdom HIV Drug Resistance Database Tags: HIV/AIDS Source Type: research
Elton John Calls for Wider HIV Testing to End New Cases in England by 2030 Elton John Calls for Wider HIV Testing to End New Cases in England by 2030
Singer Elton John has joined leading British HIV/AIDS charities in calling for wider HIV testing to halt new transmissions in England within a decade.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - December 3, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
GSK ' s ViiV Says Study Shows Its Long-Acting HIV Shot as Effective as Gilead ' s Daily Pill GSK ' s ViiV Says Study Shows Its Long-Acting HIV Shot as Effective as Gilead ' s Daily Pill
British drugmaker GSK ' s HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - February 23, 2023 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Threat to HIV Business Spooks GlaxoSmithKline Shares Threat to HIV Business Spooks GlaxoSmithKline Shares
The threat of slowing demand and new competition in GlaxoSmithKline ' s flagship HIV drug business unnerved investors in Britain ' s biggest drugmaker on Wednesday, sending its shares down as much as 1.8 percent.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - July 6, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Prince Harry, Elton John to Launch Coalition Against HIV in Men Prince Harry, Elton John to Launch Coalition Against HIV in Men
Britain ' s Prince Harry and music star Elton John are joining forces to launch a"global coalition" focused on treating HIV infections in men, the singer ' s AIDS charity said on Thursday.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - July 13, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
GSK ' s Long Acting HIV Injection Gets Boost From Study GSK ' s Long Acting HIV Injection Gets Boost From Study
GlaxoSmithKline ' s experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - August 24, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
GSK ' s ViiV Seeks Marketing License for Baby-Friendly HIV Pill GSK ' s ViiV Seeks Marketing License for Baby-Friendly HIV Pill
British drugmaker GSK applied on Friday for a license to market its HIV drug dolutegravir in a formulation designed to be easier for babies and children who are living with the virus to swallow.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - December 17, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
GSK Says Long-Acting HIV Prevention Drug 65% More Effective Than Truvada GSK Says Long-Acting HIV Prevention Drug 65% More Effective Than Truvada
Britain ' s GSK said on Tuesday that an injection of its cabotegravir drug given every two months was found to be 65% more effective in preventing HIV infections than Gilead ' s Truvada daily oral pills.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - July 8, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Cheap Copies of GSK ' s HIV Prevention Drug Could Be Ready in 2026 Cheap Copies of GSK ' s HIV Prevention Drug Could Be Ready in 2026
British drugmaker GSK has struck a deal to allow low-cost generic versions of its long-acting HIV preventive medicine to be used in the developing world, including sub-Saharan Africa.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - July 29, 2022 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Do People Living With HIV Age Prematurely? Do People Living With HIV Age Prematurely?
People living with HIV may develop cardiovascular disease and hypertension earlier and be increasingly prone to chronic kidney disease, researchers in the United Kingdom report.Medscape Medical News
Source: Medscape Hiv-Aids Headlines - August 29, 2022 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Missed opportunities for prevention of vertical HIV transmission in Canada, 1997-2016: a surveillance study.
Abstract
BACKGROUND: Vertical HIV transmission has declined in Canada, but missed opportunities for prevention continue to occur. We sought to determine the adequacy, and changes over time in adequacy, of uptake of maternal and neonatal antiretroviral therapy for the prevention of vertical HIV transmission, and to determine the vertical transmission rate over time and according to adequacy of antenatal antiretroviral therapy during the combination antiretroviral therapy era in Canada.
METHODS: The Canadian Perinatal HIV Surveillance Program collects data annually through retrospective chart review concerning ...
Source: cmaj - May 10, 2018 Category: General Medicine Authors: Bitnun A, Lee T, Brophy J, Samson LM, Kakkar F, Vaudry W, Tan B, Money DM, Singer J, Sauvé LJ, Alimenti A, Canadian Perinatal HIV Surveillance Program Tags: CMAJ Open Source Type: research
‘London Patient’ Appears to Become the Second Person Ever Cured of HIV
Doctors say a British man who previously tested positive for HIV might be the second person ever to be cured of the virus that causes AIDS.
Reuters reports that the man, whose identity has not been revealed, has tested negative for the virus almost three years after he received a bone marrow transplant from a donor with an HIV-resistant genetic mutation. The man stopped taking antiretroviral drugs 18 months ago.
“There is no virus there that we can measure. We can’t detect anything,” Ravindra Gupta, the doctor who co-lead the man’s treatment team, told Reuters.
The man, who has been dubbed the ̶...
Source: TIME: Health - March 5, 2019 Category: Consumer Health News Authors: Amy Gunia Tags: Uncategorized health HIV/AIDS onetime overnight Source Type: news
The Impact of Treatment as Prevention on the HIV Epidemic in British Columbia, Canada
This study proposes to describe the impact of a publicly funded Treatment as Prevention (TasP) strategy in British Columbia (BC), Canada, in decreasing the individual and public health impact of the HIV/AIDS Epidemic.Recent FindingsIn BC, TasP has been associated with a steady decline in HIV-related morbidity and mortality. At the same time, a demographic transition was observed among people living with HIV (PLWH), with the majority of those on antiretroviral treatment (ART) now ≥ 50 years of age, living with at least one comorbidity, and dying from age-associated comorbidities. We also documented a progressive increa...
Source: Current HIV/AIDS Reports - March 2, 2020 Category: Infectious Diseases Source Type: research
An observational study of initial HIV RNA decay following initiation of combination antiretroviral treatment during pregnancy.
CONCLUSIONS: Only high baseline pVL independently contributed to a faster rate of first-phase viral half-life decay. pVL at 14 days after initiating cART allows early identification of treatment failure. In the first 14 days after initiating cART in pregnancy, integrase inhibitor-based cART reduced maternal pVL faster than protease inhibitor- and non-nucleoside reverse transcriptase-based cART. While our study findings support INSTI use when initiated in pregnancy especially when initiated at later gestations and in those with higher baseline pVL, other non-INSTI based cART with more data on safety in pregnancy also perf...
Source: AIDS Research and Therapy - July 12, 2020 Category: Infectious Diseases Authors: Alagaratnam J, Peters H, Francis K, Kay N, Gilleece Y, Finnerty FP, Grimes RE, Parry S, Portman M, Wait BC, Shah R, Roedling S, Hawkins DA, Chitty S, Sarner L, Marcus R, Hartley A, Nori AV, Rosenvinge M, Taylor GP, London HIV Perinatal Research Group Tags: AIDS Res Ther Source Type: research
